Other products are Repatha, Blincyto, Vectibix, Nplate, Kyprolis ... rating. Shares of Amgen are trading at a forward earnings multiple of 16.4X, as well as a PEG Ratio of 2.8, a Price/Cash Flow ratio ...

Currently, Amgen Inc.’s price-earnings ratio is 41.1. Amgen Inc.’s trailing 12-month revenue is $32.5 billion with a 13.0% net profit margin. Year-over-year quarterly sales growth most recently was 23 ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

On October 16, Goldman Sachs reaffirmed its Conviction Buy rating on Amgen Inc. (NASDAQ:AMGN) with a price target of $369.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor Soliris (eculizumab), which contributed $3.1 billion in global revenues to AZ last year.

The ODYSSEY OUTCOMES data, backed with a public commitment to work with payers to reduce prices in patients who stand to benefit the most, is the perfect riposte to Amgen. Both drugs were approved ...